Meet the Oxeia Team

​We've been telling you about the science behind OXE103. Now we're giving you a chance to meet the people building it on a live webinar with CEO Michael Wyand, Chief Scientific Officer Dr. Vishal Bansal, and board member, Alex Smith.

​This is a look behind the science at the people driving Oxeia's research, regulatory strategy, and path toward FDA approval. Michael brings 30 years of FDA regulatory and clinical development experience. Vishal is the trauma surgeon whose research on ghrelin at UCSD became the foundation for OXE103. Alex, a former NFL quarterback, joined Oxeia's board after his own experience with concussion and has been a vocal advocate for real treatment options.

​Together, they'll cover what our Phase 2a trial showed, what Phase 2b is designed to test, and why the FDA cleared OXE103 to move forward with no additional safety studies required.

​It all takes place Thursday, September 17, at 11am PT.

​Reserve your spot today, and get your questions ready. We look forward to meeting you.

​This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

​OXE103 is an investigational therapy subject to regulatory review and clinical development risk.